Activartis cancer immune therapy wins European orphan drug designation
AV0113, which was developed against every type of cancer, is based on a procedure where the immune system will be prepared to combat tumour thereby controlling the growth.
Anixa Biosciences has secured a patent from the Korean Ministry of Intellectual Property (MOIP) for its breast cancer vaccine technology.
CGI will leverage its SelectOne program that includes proprietary genomic assays in CLL, data and logistics management, and comprehensive CLIA- and CAP-accredited clinical laboratory testing. Using CGI’s comprehensive
The bactericidal, once-daily injectable lipoglycopeptide antibacterial agent is indicated for nosocomial pneumonia, including ventilator-associated pneumonia, believed to be caused by methicillin resistant Staphylococcus aureus when no other alternatives